Angiogenesis and liver fibrosis

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 377-391

  Elpek, Gülsüm Özlem ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Chronic liver disease; Cirrhosis; Fibrogenesis; Hepatic stellate cells; Hypoxia; Liver fibrosis; Vascular endothelial growth factor

Indexed keywords

EID: 84928953152     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.377     Document Type: Article

References (147)

1. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399-408 [PMID: 22304911 DOI:10.1016/j.cell.2012.01.021]
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307 [PMID:21593862 DOI: 10.1038/nature10144]
3. Valfrè di Bonzo L, Novo E, Cannito S, Busletta C, Paternostro C, Povero D, Parola M. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-1341 [PMID: 19688698]
4. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009; 16:167-179 [PMID: 19217420 DOI: 10.1016/j.devcel.2009.01.003]
5. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620 [PMID:19157625 DOI: 10.1016/j.jhep.2008.12.011]
6. Kukla M, Gabriel A, Waluga M, Budak R, Mazur W. Angiogenesis in chronic viral hepatitis. Gastroenterol Pol 2009; 16:304-309
7. Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann Hepatol 2007; 6:170-173 [PMID: 17786144]
8. Gabriel A, Kukla M, Wilk M, Liszka Ł, Petelenz M, Musialik J. Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage. Pathol Res Pract 2009; 205:758-764 [PMID: 19592175 DOI: 10.1016/j.prp.2009.06.007]
9. Kukla M, Gabriel A, Sabat D, Liszka Ł, Wilk M, Petelenz M, Musialik J, Dzindziora-Frelich I. Association between liver steatosis and angiogenesis in chronic hepatitis C. Pol J Pathol 2010; 61:154-160 [PMID: 21225498]
10. Ciupińska-Kajor M, Hartleb M, Kajor M, Kukla M, Wylezoł M, Lange D, Liszka L. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int 2013; 7: 233-240 [PMID: 23519653 DOI: 10.1007/s12072-011-9320-9]
11. Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology 2009; 49: 1066-1068 [PMID: 19330868 DOI: 10.1002/hep.22872]
12. Sanz-Cameno P, Trapero-Marugán M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; 2010: 272170 [PMID:20592752 DOI: 10.1155/2010/272170]
13. Bruno A, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan DM, Mortara L. Orchestration of angiogenesis by immune cells. Front Oncol 2014; 4: 131 [PMID: 25072019 DOI: 10.3389/ fonc.2014.00131]
14. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594.e1 [PMID: 25066692 DOI:10.1053/j.gastro.2014.06.043]
15. Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 2014; 548: 20-37 [PMID: 24631571 DOI:10.1016/j.abb.2014.02.015]
16. Tecchio C, Cassatella MA. Neutrophil-derived cytokines involved in physiological and pathological angiogenesis. Chem Immunol Allergy 2014; 99: 123-137 [PMID: 24217606 DOI: 10.1159/000353358]
17. Bosisio D, Salvi V, Gagliostro V, Sozzani S. Angiogenic and antiangiogenic chemokines. Chem Immunol Allergy 2014; 99:89-104 [PMID: 24217604 DOI: 10.1159/000353317]
18. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci (Lond) 2003; 104: 47-63 [PMID: 12519087 DOI: 10.1042/ CS20020137]
19. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30: 258-270 [PMID: 20665378 DOI: 10.1055/s-0030-1255355]
20. Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009; 296: G582-G592 [PMID:19136383 DOI: 10.1152/ajpgi.90368.2008]
21. Novo E, Povero D, Busletta C, Paternostro C, di Bonzo LV, Cannito S, Compagnone A, Bandino A, Marra F, Colombatto S, David E, Pinzani M, Parola M. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J Pathol 2012; 226: 588-597 [PMID: 21959987 DOI: 10.1002/ path.3005]
22. Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 2010; 16: 281-288 [PMID: 20082471 DOI:10.3748/wjg.v16.i3.281]
23. Yang Y, Sun M, Wang L, Jiao B. HIFs, angiogenesis, and cancer. J Cell Biochem 2013; 114: 967-974 [PMID: 23225225 DOI: 10.1002/ jcb.24438]
24. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012; 55: 622-633 [PMID:22120903 DOI: 10.1002/hep.25497]
25. Lampugnani MG. Endothelial adherens junctions and the actin cytoskeleton: an 'infinity net'? J Biol 2010; 9: 16 [PMID: 20377920 DOI: 10.1186/jbiol232]
26. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004; 5: 261-270 [PMID: 15071551 DOI: 10.1038/ nrm1357]
27. Chien S, Li S, Shiu YT, Li YS. Molecular basis of mechanical modulation of endothelial cell migration. Front Biosci 2005; 10:1985-2000 [PMID: 15769679 DOI: 10.2741/1673]
28. Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol 2013; 19:1707-1717 [PMID: 23555159 DOI: 10.3748/wjg.v19.i11.1707]
29. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013; 328: 18-26 [PMID: 22922303 DOI: 10.1016/ j.canlet.2012.08.018]
30. Siefert SA, Sarkar R. Matrix metalloproteinases in vascular physiology and disease. Vascular 2012; 20: 210-216 [PMID:22896663 DOI: 10.1258/vasc.2011.201202]
31. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22 [PMID: 20029421 DOI: 10.1038/nrc2748]
32. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-921 [PMID: 12205444 DOI:10.1038/nm0902-918]
33. Gálvez BG, Matías-Román S, Albar JP, Sánchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 2001; 276:37491-37500 [PMID: 11448964 DOI: 10.1074/jbc.M104094200]
34. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676 [PMID: 12778165 DOI:10.1038/nm0603-669]
35. Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007; 170: 1942-1953 [PMID: 17525262 DOI: 10.2353/ ajpath.2007.060887]
36. Gacche RN, Meshram RJ. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Biochim Biophys Acta 2014; 1846: 161-179 [PMID: 24836679 DOI:10.1016/j.bbcan.2014.05.002]
37. Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006; 25: 373-385 [PMID: 17006765 DOI: 10.1007/s10555-006-9011-5]
38. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Lüthi U, Barberis A, Benjamin LE, Mäkinen T, Nobes CD, Adams RH. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010; 465: 483-486 [PMID: 20445537 DOI: 10.1038/ nature09002]
39. Zachary I. Neuropilins: role in signalling, angiogenesis and disease. Chem Immunol Allergy 2014; 99: 37-70 [PMID: 24217602 DOI: 10.1159/000354169]
40. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693 [PMID: 12778167 DOI: 10.1038/nm0603-685]
41. Hellström M, Gerhardt H, Kalén M, Li X, Eriksson U, Wolburg H, Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001; 153: 543-553 [PMID: 11331305 DOI: 10.1083/jcb.153.3.543]
42. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21:1743-1753 [PMID: 11927558 DOI: 10.1093/emboj/21.7.1743]
43. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463 [PMID: 10742156 DOI: 10.1038/74725]
44. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195 [PMID: 15122744 DOI: 10.1002/hep.20193]
45. Camenisch G, Pisabarro MT, Sherman D, Kowalski J, Nagel M, Hass P, Xie MH, Gurney A, Bodary S, Liang XH, Clark K, Beresini M, Ferrara N, Gerber HP. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem 2002; 277: 17281-17290 [PMID: 11877390 DOI: 10.1074/jbc.M109768200]
46. Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins:emerging targets for treatment of obesity and related metabolic diseases. FEBS J 2011; 278: 559-564 [PMID: 21182596 DOI:10.1111/j.1742-4658.2010.07979.x]
47. Bozova S, Elpek GO. Hypoxia-inducible factor-1alpha expression in experimental cirrhosis: correlation with vascular endothelial growth factor expression and angiogenesis. APMIS 2007; 115:795-801 [PMID: 17614845 DOI: 10.1111/j.1600-0463.2007. apm_610.x]
48. Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression. Hepatology Int 2013; 7: 4-12 [DOI:10.1007/s12072-012-9391-2]
49. Parola M, Marra F, Pinzani M. Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med 2008; 29: 58-66 [PMID: 18022682 DOI: 10.1016/ j.mam.2007.09.002]
50. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004; 36: 231-242 [PMID: 15115333 DOI:10.1016/j.dld.2004.01.003]
51. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011; 31: 146-162 [PMID: 21073649 DOI:10.1111/j.1478-3231.2010.02369.x]
52. Huang Y, Li S. Detection of characteristic sub pathway network for angiogenesis based on the comprehensive pathway network. BMC Bioinformatics 2010; 11 Suppl 1: S32 [PMID: 20122205 DOI:10.1186/1471-2105-11-S1-S32]
53. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-437 [PMID: 18500244 DOI: 10.1038/nrc2397]
54. Ko HM, Seo KH, Han SJ, Ahn KY, Choi IH, Koh GY, Lee HK, Ra MS, Im SY. Nuclear factor kappaB dependency of plateletactivating factor-induced angiogenesis. Cancer Res 2002; 62:1809-1814 [PMID: 11912159]
55. Raevens S, Coulon S, Van Steenkiste C, Colman R, Verhelst X, Van Vlierberghe H, Geerts A, Perkmann T, Horvatits T, Fuhrmann V, Colle I. Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome. Liver Int 2014 Apr 28; Epub ahead of print [PMID: 24766195 DOI: 10.1111/ liv.12579]
56. Franceschini B, Ceva-Grimaldi G, Russo C, Dioguardi N, Grizzi F. The complex functions of mast cells in chronic human liver diseases. Dig Dis Sci 2006; 51: 2248-2256 [PMID: 17103041 DOI:10.1007/s10620-006-9082-8]
57. Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat Med 2006; 12: 171-172 [PMID: 16462798 DOI: 10.1038/ nm0206-171]
58. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, Friedman SL. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127: 870-882 [PMID: 15362042 DOI:10.1053/j.gastro.2004.04.062]
59. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105 [PMID: 16265071 DOI: 10.1038/ ncpgasthep0055]
60. Kukla M, Berdowska A, Gabriel A, Sawczyn T, Mazur W, Sobala-Szczygieł B, Grzonka D, Zajęcki W, Tomaszek K, Bułdak RJ, Zwirska-Korczala K. Association between hepatic angiogenesis and serum adipokine profile in non-obese chronic hepatitis C patients. Pol J Pathol 2011; 62: 218-228 [PMID: 22246907]
61. Friedman SL. Transcriptional regulation of stellate cell activation. J Gastroenterol Hepatol 2006; 21 Suppl 3: S79-S83 [PMID:16958680 DOI: 10.1111/j.1440-1746.2006.04585.x]
62. Wang YQ, Luk JM, Ikeda K, Man K, Chu AC, Kaneda K, Fan ST. Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 2004; 317: 358-362 [PMID: 15063765 DOI: 10.1016/ j.bbrc.2004.03.050]
63. Zhang F, Kong D, Chen L, Zhang X, Lian N, Zhu X, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-γ interrupts angiogenic signal transduction by transrepression of platelet-derived growth factor-β receptor in hepatic stellate cells. J Cell Sci 2014; 127:305-314 [PMID: 24259663 DOI: 10.1242/jcs.128306]
64. Witek RP, Yang L, Liu R, Jung Y, Omenetti A, Syn WK, Choi SS, Cheong Y, Fearing CM, Agboola KM, Chen W, Diehl AM. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009; 136: 320-330.e2 [PMID: 19013163 DOI: 10.1053/ j.gastro.2008.09.066]
65. Sahin H, Wasmuth HE. Chemokines in tissue fibrosis. Biochim Biophys Acta 2013; 1832: 1041-1048 [PMID: 23159607 DOI:10.1016/j.bbadis.2012.11.004]
66. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008; 28:1928-1936 [PMID: 18757292 DOI: 10.1161/ATVBAHA.108.162925]
67. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609 [PMID: 16046180 DOI: 10.1016/ j.cytogfr.2005.04.007]
68. Sulpice E, Contreres JO, Lacour J, Bryckaert M, Tobelem G. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 2004; 271: 3310-3318 [PMID: 15291808 DOI: 10.1111/j.1432-1033.2004.04263.x]
69. Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, Mukhopadhyay D, Schuppan D, Bi Y, Simonetto D, Shah VH. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146: 1339-1350.e1 [PMID:24503129 DOI: 10.1053/j.gastro.2014.01.061]
70. Sahin H, Borkham-Kamphorst E, Kuppe C, Zaldivar MM, Grouls C, Al-samman M, Nellen A, Schmitz P, Heinrichs D, Berres ML, Doleschel D, Scholten D, Weiskirchen R, Moeller MJ, Kiessling F, Trautwein C, Wasmuth HE. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012; 55:1610-1619 [PMID: 22237831 DOI: 10.1002/hep.25545]
71. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348 [PMID: 16317688 DOI: 10.1002/hep.20965]
72. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983-991 [PMID:17006938 DOI: 10.1002/hep.21338]
73. Anagnostoulis S, Karayiannakis AJ, Lambropoulou M, Efthimiadou A, Polychronidis A, Simopoulos C. Human leptin induces angiogenesis in vivo. Cytokine 2008; 42: 353-357 [PMID: 18448353 DOI: 10.1016/j.cyto.2008.03.009]
74. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365 [PMID: 18093986 DOI: 10.1093/cvr/cvm111]
75. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells:chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010; 391: 1762-1768 [PMID: 20044979 DOI: 10.1016/ j.bbrc.2009.12.150]
76. Robertson SA, Rae CJ, Graham A. Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NO-dependent pathways. Regul Pept 2009; 152: 41-47 [PMID: 18722482 DOI:10.1016/j.regpep.2008.07.008]
77. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004; 101:2476-2481 [PMID: 14983034 DOI: 10.1073/pnas.0308671100]
78. Kukla M, Mazur W, Bułdak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med 2011; 17: 1397-1410 [PMID: 21738955 DOI: 10.2119/molmed.2010.00105]
79. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101 [PMID: 18602801 DOI:10.1016/j.pathophys.2008.05.001]
80. Raucci R, Rusolo F, Sharma A, Colonna G, Castello G, Costantini S. Functional and structural features of adipokine family. Cytokine 2013; 61: 1-14 [PMID: 23022179 DOI: 10.1016/j.cyto.2012.08.036]
81. Fu BD, Yamawaki H, Okada M, Hara Y. Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells. J Vet Med Sci 2009; 71: 1201-1207 [PMID:19801900 DOI: 10.1292/jvms.71.1201]
82. Aleffi S, Navari N, Delogu W, Galastri S, Novo E, Rombouts K, Pinzani M, Parola M, Marra F. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2011; 301:G210-G219 [PMID: 21252047 DOI: 10.1152/ajpgi.00047.2010]
83. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917 [PMID: 20303879 DOI: 10.1016/j.cell.2010.02.034]
84. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004; 325:395-400 [PMID: 15530405 DOI: 10.1016/j.bbrc.2004.10.042]
85. Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, Morales-Ruiz M, Bernardi M, Arroyo V, Jiménez W. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008; 48: 1193-1201 [PMID: 18816630 DOI: 10.1002/ hep.22467]
86. Melgar-Lesmes P, Casals G, Pauta M, Ros J, Reichenbach V, Bataller R, Morales-Ruiz M, Jimenez W. Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 2010; 151: 5306-5314 [PMID: 20843995 DOI:10.1210/en.2010-0754]
87. Isom HC, McDevitt EI, Moon MS. Elevated hepatic iron: a confounding factor in chronic hepatitis C. Biochim Biophys Acta 2009; 1790: 650-662 [PMID: 19393721 DOI: 10.1016/ j.bbagen.2009.04.009]
88. Vecchi C, Montosi G, Zhang K, Lamberti I, Duncan SA, Kaufman RJ, Pietrangelo A. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325: 877-880 [PMID:19679815 DOI: 10.1126/science.1176639]
89. Paridaens A, Laukens D, Vandewynckel YP, Coulon S, Van Vlierberghe H, Geerts A, Colle I. Endoplasmic reticulum stress and angiogenesis: is there an interaction between them? Liver Int 2014; 34: e10-e18 [PMID: 24393274 DOI: 10.1111/liv.12457]
90. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011; 54: 795-809 [PMID: 21145844 DOI:10.1016/j.jhep.2010.11.005]
91. Tripathi D. Primary prophylaxis against gastric variceal bleeding:is there a sticky solution at last? Hepatology 2011; 54: 1094-1096 [PMID: 22179988 DOI: 10.1002/hep.24499]
92. Plein A, Fantin A, Ruhrberg C. Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability. Microcirculation 2014; 21:315-323 [PMID: 24521511 DOI: 10.1111/micc.12124]
93. Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, Routray C, Abdelmoneim S, Vasdev M, Leof E, Charlton M, Watts RJ, Mukhopadhyay D, Shah VH. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest 2010; 120: 2379-2394 [PMID:20577048 DOI: 10.1172/JCI41203]
94. Troeger JS, Schwabe RF. Neuropilin and liver fibrosis: hitting three birds with one stone? Hepatology 2011; 54: 1091-1093 [PMID:22179987 DOI: 10.1002/hep.24484]
95. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11: 53-67 [PMID: 17222790 DOI: 10.1016/j.ccr.2006.10.018]
96. Mazzanti R, Messerini L, Monsacchi L, Buzzelli G, Zignego AL, Foschi M, Monti M, Laffi G, Morbidelli L, Fantappié O, Bartoloni Saint Omer F, Ziche M. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997; 25: 229-234 [PMID: 8985296 DOI: 10.1002/hep.510250142]
97. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004; 57:867-871 [PMID: 15280410 DOI: 10.1136/jcp.2003.015784]
98. Mazzanti R, Messerini L, Comin CE, Fedeli L, Ganne-Carrie N, Beaugrand M. Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients. World J Gastroenterol 2007; 13: 5009-5014 [PMID: 17854145]
99. Zwirska-Korczala K, Kukla M, Ziołkowski A. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp Clin Hep 2005; 1:60-65
100. Medina J, Caveda L, Sanz-Cameno P, Arroyo AG, Martín-Vílchez S, Majano PL, García-Buey L, Sánchez-Madrid F, Moreno-Otero R. Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J Hepatol 2003; 38: 660-667 [PMID: 12713878 DOI:10.1016/S0168-8278(03)00053-9]
101. Pereira Tde A, Witek RP, Syn WK, Choi SS, Bradrick S, Karaca GF, Agboola KM, Jung Y, Omenetti A, Moylan CA, Yang L, Fernandez-Zapico ME, Jhaveri R, Shah VH, Pereira FE, Diehl AM. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest 2010; 90: 1690-1703 [PMID: 20697376 DOI: 10.1038/ labinvest.2010.147]
102. Vrancken K, Paeshuyse J, Liekens S. Angiogenic activity of hepatitis B and C viruses. Antivir Chem Chemother 2012; 22:159-170 [PMID: 22182803 DOI: 10.3851/IMP1987]
103. Cuninghame S, Jackson R, Zehbe I. Hypoxia-inducible factor 1 and its role in viral carcinogenesis. Virology 2014; 456-457:370-383 [PMID: 24698149 DOI: 10.1016/j.virol.2014.02.027]
104. Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007; 81: 10249-10257 [PMID: 17626077 DOI: 10.1128/ JVI.00763-07]
105. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005; 13: 159-163 [PMID:15817385 DOI: 10.1016/j.tim.2005.02.004]
106. Abe M, Koga H, Yoshida T, Masuda H, Iwamoto H, Sakata M, Hanada S, Nakamura T, Taniguchi E, Kawaguchi T, Yano H, Torimura T, Ueno T, Sata M. Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1α axis under hypoxic conditions. Hepatol Res 2012; 42: 591-600 [PMID:22221855 DOI: 10.1111/j.1872-034X.2011.00953.x]
107. Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Borque MJ, López-Cabrera M, Moreno-Otero R. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 696-701 [PMID: 16104024 DOI: 10.1002/ hep.20828]
108. Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Moreno-Otero R. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005; 22:23-30 [PMID: 15963076 DOI: 10.1111/j.1365-2036.2005.02532.x]
109. Mee CJ, Farquhar MJ, Harris HJ, Hu K, Ramma W, Ahmed A, Maurel P, Bicknell R, Balfe P, McKeating JA. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 2010; 138:1134-1142 [PMID: 19944696 DOI: 10.1053/j.gastro.2009.11.047]
110. Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009; 49: 1469-1482 [PMID: 19235829 DOI: 10.1002/hep.22849]
111. Liaskou E, Karikoski M, Reynolds GM, Lalor PF, Weston CJ, Pullen N, Salmi M, Jalkanen S, Adams DH. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011; 53: 661-672 [PMID: 21225644 DOI: 10.1002/hep.24085]
112. Rowe IA, Galsinh SK, Wilson GK, Parker R, Durant S, Lazar C, Branza-Nichita N, Bicknell R, Adams DH, Balfe P, McKeating JA. Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology 2014; 59: 375-384 [PMID:23775568 DOI: 10.1002/hep.26571]
113. Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004; 11: 91-96 [PMID:14738564 DOI: 10.1046/j.1365-2893.2003.00483.x]
114. Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W, Wozniak-Grygiel E, Kryczka W. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat 2010; 17: 661-667 [PMID: 20002564 DOI: 10.1111/j.1365-2893.2009.01224.x]
115. Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Berdowska A, Rybus-Kalinowska B, Kalinowski M, Janczewska-Kazek E, Woźniak-Grygiel E, Kryczka W. Visfatin serum levels in chronic hepatitis C patients. J Viral Hepat 2010; 17: 254-260 [PMID:19840367 DOI: 10.1111/j.1365-2893.2009.01174.x]
116. Chau DK, Chen GG, Zhang H, Leung BC, Chun S, Lai PB. Differential functions of C- and N-terminal hepatitis B x protein in liver cells treated with doxorubicin in normoxic or hypoxic condition. PLoS One 2012; 7: e50118 [PMID: 23209654 DOI:10.1371/journal.pone.0050118]
117. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One 2012; 7: e41931 [PMID: 22848663 DOI: 10.1371/ journal.pone.0041931.]
118. Demidenko ZN, Blagosklonny MV. The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. Cell Cycle 2011; 10: 1557-1562 [PMID: 21521942 DOI: 10.4161/cc.10.10.15789]
119. Cichoz-Lach H, Celiński K, Słomka M, Kasztelan-Szczerbińska B. Pathophysiology of portal hypertension. J Physiol Pharmacol 2008; 59 Suppl 2: 231-238 [PMID: 18812641]
120. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008; 48 Suppl 1: S68-S92 [PMID: 18304681 DOI: 10.1016/j.jhep.2008.01.021]
121. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portalsystemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-894 [PMID: 14988842 DOI:10.1053/j.gastro.2003.12.012]
122. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010; 53: 558-567 [PMID: 20561700 DOI: 10.1016/j.jhep.2010.03.021]
123. D'Amico M, Mejías M, García-Pras E, Abraldes JG, García-Pagán JC, Fernández M, Bosch J. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1191-G1198 [PMID: 22403792 DOI: 10.1152/ajpgi.00252.2011]
124. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256 [PMID: 19137587 DOI: 10.1002/ hep.22758]
125. Hernández-Guerra M, García-Pagán JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, Bosch J. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006; 43: 485-491 [PMID:16496307 DOI: 10.1002/hep.21080]
126. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, Colomer D, Fernández M, Bosch J, Garcia-Pagán JC. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52 [PMID:16799985 DOI: 10.1002/hep.21228]
127. Chan CC, Tsai SC, Cheng LY, Lee FY, Lin HC. Hemodynamic assessment of the development of portal-systemic collaterals in portal hypertensive rats. Dig Dis Sci 2011; 56: 417-424 [PMID:20635149 DOI: 10.1007/s10620-010-1302-6]
128. Geerts AM, Vanheule E, Van Vlierberghe H, Leybaert L, Van Steenkiste C, De Vos M, Colle I. Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice. Hepatol Res 2008; 38: 1130-1139 [PMID:18564143 DOI: 10.1111/j.1872-034X.2008.00369.x]
129. Rodríguez-Vilarrupla A, Laviña B, García-Calderó H, Russo L, Rosado E, Roglans N, Bosch J, García-Pagán JC. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol 2012; 56: 1033-1039 [PMID:22245887 DOI: 10.1016/j.jhep.2011.12.008]
130. Huang HC, Wang SS, Hsin IF, Chang CC, Lee FY, Lin HC, Chuang CL, Lee JY, Hsieh HG, Lee SD. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012; 56: 248-258 [PMID:22290687 DOI: 10.1002/hep.25625]
131. Bellentani S, Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 Suppl 1:S4-S8 [PMID: 19381118]
132. Sanal MG. The blind men 'see' the elephant-the many faces of fatty liver disease. World J Gastroenterol 2008; 14: 831-844 [PMID:18240340 DOI: 10.3748/wjg.14.831]
133. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-393 [PMID: 15368443 DOI: 10.1002/hep.20302]
134. Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15:5193-5199 [PMID: 19891019 DOI: 10.3748/wjg.15.5193]
135. Qu A, Taylor M, Xue X, Matsubara T, Metzger D, Chambon P, Gonzalez FJ, Shah YM. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 2011; 54: 472-483 [PMID:21538443 DOI: 10.1002/hep.24400]
136. Liu Y, Ma Z, Zhao C, Wang Y, Wu G, Xiao J, McClain CJ, Li X, Feng W. HIF-1α and HIF-2α are critically involved in hypoxiainduced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation. Toxicol Lett 2014; 226: 117-123 [PMID: 24503013 DOI: 10.1016/j.toxlet.2014.01.033]
137. Fletcher AM, Bregman CL, Woicke J, Salcedo TW, Zidell RH, Janke HE, Fang H, Janusz WJ, Schulze GE, Mense MG. Incisor degeneration in rats induced by vascular endothelial growth factor/ fibroblast growth factor receptor tyrosine kinase inhibition. Toxicol Pathol 2010; 38: 267-279 [PMID: 20100840 DOI: 10.1177/0192623309357950]
138. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421 [PMID: 18081738 DOI: 10.1111/j.1365-2036.2007.03586.x]
139. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Ciupinska-Kajor M, Berdowska A, Wozniak-Grygiel E, Buldak R. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010; 45: 235-242 [PMID:20095887 DOI: 10.3109/00365520903443852]
140. Shirai Y, Yoshiji H, Noguchi R, Kaji K, Aihara Y, Douhara A, Moriya K, Namisaki T, Kawaratani H, Fukui H. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2013; 28: 723-730 [PMID: 23301938 DOI:10.1111/jgh.12112]
141. Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, Aihara Y, Namisaki T, Yoshii J, Yanase K, Tsujimoto T, Kawaratani H, Fukui H. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1094-G1104 [PMID: 21372165 DOI: 10.1152/ ajpgi.00365.2010]
142. Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Aihara Y, Shirai Y, Namisaki T, Kitade M, Douhara A, Moriya K, Fukui H. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Hepatol Res 2013; 43: 765-774 [PMID: 23163573 DOI: 10.1111/ hepr.12008]
143. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol 2013; 48: 491-503 [PMID: 22886508 DOI: 10.1007/ s00535-012-0651-7]
144. Aihara Y, Yoshiji H, Noguchi R, Kaji K, Namisaki T, Shirai Y, Douhara A, Moriya K, Kawaratani H, Fukui H. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res 2013; 43: 1241-1250 [PMID: 23448275 DOI: 10.1111/hepr.12081]
145. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S, Fukui H. Inhibition of reninangiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22-30 [PMID: 12076858 DOI: 10.1016/S0168-8278(02)00104-6]
146. Das SK, Mukherjee S, Vasudevan DM. Effects of long term ethanol consumption mediated oxidative stress on neovessel generation in liver. Toxicol Mech Methods 2012; 22: 375-382 [PMID: 22394347 DOI: 10.3109/15376516.2012.666651]
147. Raskopf E, Gonzalez Carmona MA, Van Cayzeele CJ, Strassburg C, Sauerbruch T, Schmitz V. Toxic damage increases angiogenesis and metastasis in fibrotic livers via PECAM-1. Biomed Res Int 2014; 2014: 712893 [PMID: 24734240 DOI: 10.1155/2014/712893]